Centene price target lowered to $85 from $95 at Oppenheimer

Oppenheimer analyst Michael Wiederhorn lowered the firm’s price target on Centene (CNC) to $85 from $95 and keeps an Outperform rating on the shares. Cenete’s guidance for 2025 is solid, reflecting arious moving parts including Medicaid margin recovery, tough Marketplace comps, the MA path toward break-even and the Part D changes, the analyst tells investors in a research note. The potential tailwinds from the continued Medicaid recovery, MA rebound, and PDP margin upside outweigh the enhanced Advanced Premium Tax Credits risks looking toward 2026, 2027, and beyond, Oppenheimer says.